Drugs / ANB032
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05935085 | Jun 2023 → Oct 2024 | atopic eczema | AnaptysBio, Inc. | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | AnaptysBio, Inc. | Results Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis anaptysbio.com ↗
ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. |
| 2022-04-27 | AnaptysBio, Inc. | Results AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates anaptysbio.com ↗
Top-line data demonstrated favorable safety, tolerability, and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trials. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | AnaptysBio, Inc. | Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis anaptysbio.com ↗ |
| 2023-10-11 | AnaptysBio, Inc. | Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress anaptysbio.com ↗ |
| 2022-04-27 | AnaptysBio, Inc. | AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates anaptysbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANB032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05935085 ↗ |
| Action | Activate | “BTLA agonist antibody” NCT05935085 ↗ |
| Route | Subcutaneous | “This arm will receive treatment SC” NCT05935085 ↗ |
| Target | BTLA | “BTLA agonist antibody” NCT05935085 ↗ |